Introduction
Mitochondria are the organelles with the main responsibility for energy production in cells, generated in the form of ATP by oxidative phosphorylation (OXPHOS). Mitochondria are additionally involved in many other important processes, including apoptosis and calcium homeostasis (Pozzan et al., 2000; Newmeyer and Ferguson-Miller, 2003) . Furthermore, mitochondria are the main site of the production of reactive oxygen species (ROS). The tricarboxylic acid (TCA) cycle, which in addition to its contribution to ATP production also generates several important metabolic intermediates, occurs in mitochondria (Boveris et al., 1972) .
Mitochondria contain their own genetic material, called mitochondrial DNA (mtDNA), a 16,569-bp-long, doublestranded, circular molecule containing just 37 genes. Only 13 of these genes encode proteins, all of them contributing to the formation of OXPHOS complexes through association with nuclear DNA (nDNA)-encoded proteins. The remaining genes encode 22 tRNAs and 2 rRNAs (Anderson et al., 1981) . The copy number of mtDNA varies depending on the cell type and energy demand of the tissue.
Replication of mtDNA is dependent on proteins encoded by nDNA and imported to mitochondria. Therefore, mtDNArelated diseases can be caused not only by mutations in mtDNA but also by defects in nDNA-encoded factors required for mtDNA replication (Figure 1 ). This dualdependence of mtDNA integrity is largely responsible for the heterogeneous nature of mtDNA-related diseases.
The history of research on mtDNA-related diseases is relatively short, with the first disease-causing mtDNA mutations reported in 1988 (Holt et al., 1988; Wallace et al., 1988) . These two ground-breaking studies paved the way to the discovery and characterization of a large number of mtDNA mutations, and at least 300 pathogenic mtDNA mutations have now been identified (www.mitomap.org). Due to the high degree of heterogeneity in mtDNA-related diseases, it is very hard to quantify their prevalence. Studies have been conducted to define the severity of mtDNA mutations in specific populations; however, a worldwide study in this field is missing. A study based in northeastern England reported that mtDNA-related diseases occurred at a frequency of 1 in 10,000 in working-age adults with a further 1 in 6000 people (below retirement age) at risk of developing these diseases (Schaefer et al., 2008) . Subsequent reports have suggested that the frequency of mtDNA mutations is much higher (Greaves et al., 2012) . Recent advances in molecular biology and sequencing techniques will inevitably lead to the characterization of new mtDNA mutations, which will help provide a more accurate estimate of the prevalence of these diseases, and thereby a better understanding of the impact of mtDNArelated diseases on society.
The mechanisms underlying mtDNA-related disorders can explain why they are associated with such a high degree of clinical heterogeneity. The mechanistic details of mtDNA dysfunction need to be investigated in depth in order to design novel therapeutic strategies. This review examines the state of the art regarding these mechanisms and reviews some recent therapeutic advances in the field.
Features of mtDNA genetics

The mtDNA molecule at a glance
The publication of the first sequence of human mtDNA in 1981 marked a milestone in mitochondrial research (Anderson et al., 1981) . Our current understanding of the mtDNA sequence incorporates subsequent revisions (Andrews et al., 1999) . The mtDNA molecule contains no introns and only a few noncoding bases (Anderson et al., 1981) . The molecule is formed by a guanine-rich heavy strand (H) and a cytosine-rich light strand (L). The only noncoding region in mtDNA is called the D-loop (displacement loop) and it contains control elements required for mtDNA transcription and replication (Shadel and Clayton, 1997) . Unlike the nuclear genome, which is found in 2 copies of 23 chromosomes (2n = 46), mtDNA can occur in multiple copy numbers. The maintenance of mtDNA copy number is discussed in a separate section.
mtDNA exists in protein-linked structures called nucleoids, compact macrocomplexes formed and stabilized principally through the action of mitochondrial transcription factor A (TFAM) (Kaufman et al., 2007) . mtDNA nucleoid-associated proteins are a subject of intense research but as of yet there is no consensus on their characteristics or number (Hensen et al., 2014) . Further advances in this area will provide a clearer picture on the role of nucleoid structure in mtDNA maintenance.
Maintenance and homeostasis of mtDNA is determined by various processes specialized for their function. In the following sections we review some of the key features of mtDNA in order to provide a better understanding of mtDNA-related diseases and their mechanisms. These features should be taken into account during diagnosis and treatment of mitochondrial disease patients.
Heteroplasmy and threshold
MtDNA accumulates mutations at a fast rate, leading to mitochondrial dysfunction. The inherent ROS formation associated with the OXPHOS system might be the primary cause of the accumulation of mutations in mtDNA (Brown et al., 1979) . Nonmutated and mutated mtDNA copies can coexist in the same cell and even in the same mitochondria, a condition called heteroplasmy. MtDNA mutations can also be found in a homoplasmic state, when no nonmutated mtDNA copies are present. In the heteroplasmic state, the proportion of mutated mtDNA copies needs to pass a certain threshold in order to cause a pathological defect detectable by biochemical tests. However, there is no clear correlation between the heteroplasmy level and the clinical severity of disease (Wong, 2007) , and the threshold level can vary depending on the mutation type, adding another level of complexity to the treatment of mtDNA-related disorders. A recent study showed that small changes in mtDNA heteroplasmy cause significant changes in the nDNA transcriptome (Picard et al., 2014) . This transcriptional reprogramming upon mitochondrial dysfunction is also known as retrograde signaling and is activated by changes in ATP/AMP, NADH/NAD+, ROS, cytosolic Ca
2+
, and membrane potential. These changes are interpreted by the cells as signals of mitochondrial dysfunction. Retrograde signaling further causes changes in expression of genes involved in various signaling pathways (e.g., mTOR, Myc, NFKB), mitochondrial transcription, capacity, or biogenesis and usually causes a metabolic switch towards glycolysis. The interconnected complex mechanism of this phenomenon is the subject of a recent review by our group (Cagin and Enriquez, 2015) .
Random segregation, mtDNA bottleneck, and clonal expansion
Mitochondrial segregation during cell division has been suggested to be random, which need to be investigated in deeper detail (Lombes et al., 2014) . This suggests that the segregation of mitochondria carrying mutant and wild-type mtDNA will result in one daughter cell having more mutant mtDNA and the other having more wildtype mtDNA. Random mitochondrial segregation would result in the production of daughter cells with varying proportions of putatively mutant mtDNA. If the mutant mtDNA proportion exceeds a certain threshold level, a biochemical defect will be evident. In contrast, in fastdividing cells this random segregation can result in rapid loss of mutant mtDNA, as has been observed in blood samples (Rahman et al., 2001) . Furthermore, evidence from multiple studies suggests that a bottleneck during development results in rapid segregation of heteroplasmic mtDNA, providing another route to homoplasmy (Upholt and Dawid, 1977; Olivo et al., 1983; Holt et al., 1989; Vilkki et al., 1990; Blok et al., 1997; Cree et al., 2008b) . However, the developmental phase at which the bottleneck occurs is not clearly defined and is debated.
A mosaic pattern of mtDNA is observed in COXdeficient muscle fibers of patients with mitochondrial dysfunction. The suggested mechanism responsible for this is called clonal expansion, and it is due to random replication of mtDNA resulting in cells with differing proportions of mutant to wild-type mtDNA. This will result in loss of mutant mtDNA in some cells, providing protection for those specific cells. However, the cells that accumulate mutant mtDNA will over time develop biochemical defects. Clonal expansion also happens in postmitotic cells, explaining the accumulation of mutant mtDNA with aging in muscle cells and neurons (Greaves et al., 2012) . The rapidly aging world population has generated great interest in the involvement of mitochondria in aging, and the mechanisms connecting mtDNA mechanisms to aging are central to understanding the exact roles of mitochondria in healthy aging.
Maternal inheritance
Unlike nDNA, mtDNA is transmitted to offspring uniparentally, in most animals from the mother (Giles et al., 1980) . Maternal inheritance is widely accepted among researchers; however, some published data suggest that a limited degree of paternal inheritance can occur. For example, some studies have suggested paternal inheritance of a ND2 gene mutation (Schwartz and Vissing, 2002) . The existence of a low level of paternal inheritance has been supported by subsequent studies and might account for some rare familial mtDNA diseases with no identified cause (Danan et al., 1999; Marchington et al., 2002; Filosto et al., 2003; Taylor et al., 2003b; Schwartz and Vissing, 2004) . However, maternal inheritance is far more likely and should be examined as the more likely option to track the familial history of the mutation. are heterogeneous, and in some cases the same mutation can result in different symptoms. Most point mutations that result in a clinical phenotype occur in mt-tRNA and usually result in an overall reduction in mitochondrial protein synthesis (Mariotti et al., 1994) . In contrast, mtmRNA mutations usually (but not always) result in specific respiratory complex defects (Figure 2 ). The diseasecausing heteroplasmy threshold can differ depending on the type of mutation, with mtDNA deletions usually having lower disease-causing threshold than mt-tRNA mutations (approximately 60% vs. 80%; Kirino et al., 2004; Taylor and Turnbull, 2005) .
Point mutations
In general, point mutations are heteroplasmic and highly recessive. However, there are reports of homoplasmic mtDNA point mutations affecting a single tissue and characterized by incomplete penetrance (McFarland et al., 2002; Taylor et al., 2003a; Temperley et al., 2003; McFarland et al., 2004; McFarland et al., 2007; Yang et al., 2009 ). The three most common homoplasmic mutations, causing Leber's hereditary optic neuropathy (LHON), are m.11778G > A, m.3460G > A, and m.14484T > C (McFarland et al., 2007) .
Here we focus on the three most common heteroplasmic mutations observed in patients. The commonest mttRNA mutation is the m.3243A > G mutation on mttRNA Leu(UUR) , first characterized in a subgroup of patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) (Goto et al., 1990) . More recent studies reported that this mutation mostly results in maternally inherited diabetes and deafness (MIDD) (Nesbitt et al., 2013) . The same study showed that this mutation can result in progressive external ophthalmoplegia (PEO) and that some affected individuals have overlapping symptoms (i.e. MELAS + MIDD, MELAS + PEO, MIDD + PEO). Furthermore, 9% of carriers show no clinical phenotype, and the high levels of heterogeneity makes diagnosis of the disease very challenging (Nesbitt et al., 2013) . Mechanisms of nDNA and mtDNA mutations associated with mtDNA-related diseases: mutations resulting in mtDNArelated diseases can either occur on mtDNA or nuclear genome (left, blue panel). These mutations have multiple targets, which can affect various processes (middle, green panel). These can result in a single-complex or multiple-complex defect or mtDNA loss or a shift in heteroplasmy; in all cases, OXPHOS activity is disrupted (right, red panel).
The second most common heteroplasmic point mutation is also on a tRNA gene. The m.8444A > G substitution in mt-tRNA Lys (Shoffner et al., 1990 ) mostly results in myoclonic epilepsy with ragged red fibers (MERFF) and is also linked to some cases of a MIDD-like syndrome (Santorelli et al., 1996a) . Comparison of the m.32343A > G and m.8444A > G mutations highlights the clinical heterogeneity of mtDNA-related diseases, although both cause OXPHOS defects through a decreased protein synthesis rate (Yasukawa et al., 2000) .
Clinically heterogeneous disease states also result from an amino acid substitution (Leu 156 Arg) in ATP synthase subunit 6, caused by the m.8993T > G mutation (Santorelli et al., 1996b) . This mutation is mainly linked to two diseases: NARP (neuropathy, ataxia, retinitis pigmentosa) and MILS (maternally inherited Leigh's syndrome). Interestingly, the mutation causes NARP at 90%-95% heteroplasmy and causes MILS at higher heteroplasmy rates (Tatuch et al., 1992) .
Deletions
MtDNA deletions result from defects in mtDNA replication, maintenance, and repair (Kaukonen, 2000; Spelbrink et al., 2001) . MtDNA deletions mostly occur between origins of replication (O H and O L ) and regions flanked by tandem repeat sequences (Schon et al., 1989; Krishnan et al., 2008) . Deletions are normally sporadic, occur in the germline, and are not transmitted to offspring . The size of large-scale mtDNA deletions varies, but many patients have a ~5-kb 'commondeletion' that spans the ATPase8 and ND5 genes as represented in Figure 1 (Larsson and Holme, 1992) .
The main determinants of clinical severity of a deletion seem to be its abundance and tissue distribution, rather than the size and location of the deletion itself (Tuppen et al., 2010) . However, recent studies also suggest a correlation among deletion size, heteroplasmy, and clinical severity (Grady et al., 2014) .
MtDNA deletions are frequently associated with three syndromes: Pearson syndrome, Kearns-Sayre syndrome (KSS), and chronic progressive external ophthalmoplegia (cPEO) (Zeviani et al., 1988; Moraes et al., 1989; Rotig et al., 1990) . Moreover, many studies have shown that mtDNA deletions accumulate with aging and are mainly linked to nervous system disorders (Cortopassi et al., 1992; Bender et al., 2006; Kraytsberg et al., 2006) . Increased levels of mtDNA deletions have been found in the brains of elderly individuals and in heart tissue affected by coronary atherosclerosis (Corral-Debrinski et al., 1992a , 1992b .
mtDNA copy number maintenance
In addition to direct mutations in mtDNA, mtDNA dysfunction can also be caused by mutations in nDNA (Figure 1 ). MtDNA-related nuclear genes that cause disease mainly affect mtDNA replication and copy number maintenance, and they fall into two categories: those that directly affect the mtDNA replication fork and mutations in genes that are involved in the supply of nucleotides for mtDNA replication (such as mitochondrial thymidine kinase TK2, the deoxyguanosine kinase dGK, and adenine nucleotide transporter ANT1) (Copeland, 2008) . The effects of these mutations are sometimes called secondary mtDNA defects. mtDNA copy number is regulated in accordance with the energy demand of the cell. Cells under a high energy demand, like muscle cells and neurons, thus need to maintain high numbers of healthy and functional mtDNA. This homeostasis can be disrupted either by increased replication of mtDNA or by targeted degradation of damaged mtDNA molecules (Szklarczyk et al., 2014) . There is some supporting evidence that oxidative stress can increase mtDNA degradation (Shokolenko et al., 2009; Furda et al., 2012) .
Copy number maintenance is central to healthy aging. mtDNA copy number decreases with aging in different tissues, including pancreatic islets, skeletal muscle, cerebral cortex, and heart muscle (Frahm et al., 2005; Short et al., 2005; Cree et al., 2008a) . Similar observations have been reported in model organisms, such as an age-related decrease in mtDNA copy number in the rat CNS (McInerny et al., 2009) . However, the impact of mitochondrial dysfunction on aging varies between species such as mice and humans (Greaves et al., 2011) . One study of two well-known mtDNA-related diseases, MELAS and MERRF, showed an aging-related reduction in mtDNA levels in leukocytes (Liu et al., 2006) . Mutations in the OPA1 gene, whose function is to induce mitochondrial fragmentation, result in dominant optic atrophy (Alavi and Fuhrmann, 2013) . There are conflicting results concerning whether this mutation results in mtDNA loss or mtDNA proliferation (Iommarini et al., 2012; Sitarz et al., 2012) . Further work is needed to determine the mechanisms of mtDNA replication and their involvement in disease progression.
The factors needed for mtDNA replication are completely encoded by nDNA. This adds another level of complexity to the maintenance of a healthy mtDNA population. MtDNA polymerase γ (Pol γ), a heterodimeric protein consisting of a catalytic subunit (PolgA) and a processivity subunit (polgB), is the exclusive mediator of mtDNA polymerase activity (Carrodeguas et al., 2001) . Mitochondrial DNA helicase, also called Twinkle, is responsible for 5'-3' mtDNA helicase activity, and mitochondrial single-strand binding protein (mtSSB) is responsible for the stabilization of the single strand once the double strand is unwound (Spelbrink et al., 2001) . Together with TFAM these proteins form the mitochondrial replisome, which can be reconstituted in vitro (Korhonen et al., 2004) . The mechanism of mtDNA replication is not fully defined. There are mainly two models: strand displacement and strand coupling (Clayton, 1982; Holt et al., 2000) . Both models have been critically appraised, but a detailed description of this area is beyond the scope of this review Clayton, 2003b, 2003a; Holt and Jacobs, 2003) . Pol γ is one of the most widely studied nuclear genes involved in mtDNA disorders because of its high error rate of 1:50,000 bp (Longley et al., 2001 ). More than 150 mutations in Pol γ have been identified in patients with mtDNA disorders (Human DNA Pol Gamma Mutation Database, http://tools.niehs.nih.gov/polg/). These mutations can be found in all domains of Pol γ and can cause PEO, Alpers syndrome (Naviaux and Nguyen, 2004) , ataxia neuropathy (Van Goethem et al., 2004) , and male infertility (Rovio et al., 2001) . A detailed overview of Pol γ is available in the Human DNA Pol Gamma Mutation Database (http://tools.niehs.nih.gov/polg/). 3.5. mtDNA depletion syndrome Loss of mtDNA in tissues is usually identified as mtDNA depletion syndrome (MDS). General clinical symptoms include muscle weakness, progressive encephalopathy, liver failure, and disturbed function of the skeletal muscle, kidneys, and brain (Rahman and Poulton, 2009) . MDS was first characterized as an autosomal recessive disorder (Moraes et al., 1991) and is widely reported in childhood respiratory deficiency syndromes (Sarzi et al., 2007) .
The genetic alterations leading to MDS commonly affect the mtDNA replication components (Pol γ, Twinkle, TFAM) (Spelbrink et al., 2001 ), but they can also involve genes required for the supply of sufficient dNTPs for mtDNA replication. dNTPs are supplied to mitochondria either by active transport of cytosolic dNTPs or through a salvage pathway that mainly requires TK2 (thymidine kinase 2) (Suomalainen and Isohanni, 2010) . Mutations in TK2 have been reported as the most common cause of MDS . MDS can also be triggered by mutations in dGK or ribonucleotide reductase (Bornstein et al., 2008) , and another enzyme important for maintaining the dNTP pool, TP (thymidine phosphorylase), causes the mtDNA-related disease MNGIE (mitochondrial neurogastrointestinal encephalomyopathy) (Nishino et al., 1999) .
Clinical, biochemical features, and diagnosis of mtDNA-related diseases
Clinical assessment and examination
The diagnosis of mtDNA-related diseases is quite complex, which should be extensive. The age of onset of mtDNArelated diseases is variable and is determined primarily by the severity of the defect and the mutation load and to a lesser extent by environmental and nuclear genetic modifier factors. It is common to classify mtDNA-related diseases into two groups: 'early infancy and childhood' vs.
'late childhood and adulthood' . Leigh syndrome, mtDNA depletion syndromes, KSS, and Pearson syndrome fall into the first group, while mitochondrial encephalopathy, MELAS, cPEO, neuropathy, NARP, LHON, and MERRF are usually observed in late childhood and adulthood (Tuppen et al., 2010) . The high degree of tissue heterogeneity is another hallmark of mtDNArelated diseases. Neurological, gastrointestinal, cardiac, respiratory, endocrinal, ophthalmological, hematological, renal, muscular system, and liver failure are involved in mtDNA-related diseases (Vafai and Mootha, 2012) .
In order to assess the clinical situation of a patient, the clinician should carry out various tests on the possible organ systems that could be involved in the disease. One group of these tests is based on imaging. Cardiac failure can be investigated by electrocardiography (ECG), electromyography (EMG) can reveal muscular defects, and computed tomography (CT) and magnetic resonance imaging (MRI) findings can help to evaluate the patients' condition (Menezes et al., 2014) . Certain blood-based biochemical tests have shown promise as diagnostic tools for mitochondrial disorders. Measuring the level of lactate, pyruvate, creatine kinase, total blood count, thyroid and liver function, bone chemistry, and blood glucose levels can be informative (Naviaux, 2004) . For example, it is common to observe high lactate and pyruvate levels in patients with mitochondrial disorders as a result of a compensatory mechanism to overcome ATP deficit; however, this is not always observed in LHON and KSS. Organic acids and amino acid profiles measured by chromatography, mass spectrometry, or HPLC can aid the observations. Although a clear correlation is missing, an increase in alanine, proline, glycine, sarcosine, and tyrosine can be observed in mtDNA-related diseases. In addition, novel biomarker discoveries are expected to help towards the diagnosis of mitochondrial disorders, thereby decreasing the diagnostic work currently required. So far, cytokine FGF-21 (fibroblast growth factor-21) has been found to be a biomarker for muscle-specific mitochondrial diseases (Suomalainen et al., 2011) .
Histopathology
Regardless of the underlying mutation, all mtDNA-related disorders result in defects in oxidative phosphorylation as shown in Figure 2 (Betts et al., 2004) . However, tissue heterogeneity and specificity remain the major reasons for the need of detailed analysis of mitochondrial function in different tissues, if possible. In order to carry out a more extensive assessment, a muscle biopsy is needed since this tissue mostly, but not always, shows a defect in most of the mtDNA-related diseases (Janssen et al., 2003) . Effective communication with the patient is needed at this stage in order to obtain a muscle biopsy sample together with a fibroblast sample, both of which can be used for subsequent analysis. One of the most established techniques is the staining of the muscle fibers with Gomori trichrome, which results in ragged red fibers (RRFs), which reflect the abnormal subsarcolemmal accumulation of mitochondria (Tuppen et al., 2010) . The most common and penetrant phenotype is COX (cytochrome c oxidase) deficiency, first reported in chronic PEO patients' fibers (Johnson et al., 1983) . COX/SDH (succinate dehydrogenase) immunohistochemical double-staining is commonly used to classify normal versus deficient cells in mitochondrial diseases. SDH staining shows a normal pattern in disorders caused only by mtDNA defects but not by nDNA (so-called primary mtDNA mutations), since all subunits of complex II are encoded by nDNA. Therefore, SDH staining can be mainly used to identify complex II defects. COX staining can result in a mosaic pattern, or in some cases, global and uniform decrease is observed. Mosaic COX deficiency highlights heteroplasmy differences; on the other hand, uniform COX defects are related to nDNA mutations mainly encoding COX subunits and assembly factors (e.g., SURF1, SCO2) (Zhu et al., 1998) . It should also be noted that COX deficiency may be observed upon aging since there is an accumulation of mtDNA mutations by age (Brierley et al., 1998) . Such cases should be classified in the context of aging rather than specific mtDNA-related diseases. Finally, more analysis can be made by measuring mitochondrial ultrastructure using electron microscopy and respiratory chain complex activities from isolated mitochondria; however, these also depend on the availability of the materials and resources. A more detailed explanation of clinical symptoms and histopathological findings was reviewed elsewhere (Taylor and Turnbull, 2005; Greaves et al., 2012) .
DNA-based diagnosis
The detailed investigation of the family history of the patient may reveal the genetic defect of the individual and help to differentiate whether it is mtDNA or nDNA related, since mtDNA has a maternal inheritance. In detail, observation of mtDNA deletions usually reflects a defect in mtDNA maintenance genes (e.g., PolG, PEO1, OPA1) and mtDNA depletion reflects defective mtDNA replication related to the replication genes (PolG, mtSSBP, Twinkle, Tfam) or genes involved in the supply of the dNTP pool (TK2, dGK). In some cases, the clinical phenotypes may reflect a common mutation causing well-defined diseases such as MELAS (m.3243A>G) or MERRF (m.8344A>G). In such cases, a direct sequencing of the genetic location or RFLP can be applied. Additionally, the heteroplasmy levels of these mutations should be determined either by RFLP or TaqMan real-time PCR analysis. Furthermore, long-range PCR or real-time PCR can be used to detect the mtDNA deletions . These primary mtDNA defects were discussed in the earlier sections of this study. Furthermore, mtDNA depletion, caused by nDNA-encoded gene mutations (for details, see Section 3), can be detected by real-time PCR. There are many cases where the disease-causing mutation on mtDNA has not been defined before. Direct sequencing of the whole mtDNA can provide much information. However, care should be taken while choosing the candidate mutation and a pathogenic disease causing mutation. The criteria for this were published by DiMauro and Schon and we refer their work for this purpose (DiMauro and Schon, 2001 ).
The improvements in sequencing technologies allowed the usage of next-generation sequencing (NGS) as a new way to diagnose mitochondrial diseases. Recent figures show that NGS allowed not only to assign already characterized mutations to patients but also to discover novel mutations (Menezes et al., 2014) . Whole-genome sequencing (WGS) is still very expensive to be used on a daily basis, but whole-exome sequencing (WES) has been used commonly in recent years. Although intronic defects can be linked to some diseases, most genetic diseases are caused by mutations present in exons (coding regions), which correspond to less than 2% of the whole genome. By using WES, all of the variants in exons can be detected in a single experiment rather than in several sequencing runs. The difficulty in this is to assign a variant as a diseasecausing variant. Here, we refer to a recent review published by Suomalainen's group for details and criteria of variant identification (Carroll et al., 2014) . A more targeted approach for mitochondrial diseases can be taken by using MitoExome, which has been proven to detect both known and novel mutations causing mitochondrial diseases. Independent studies have shown that this methodology can be applied successfully (Calvo et al., 2012; Vasta et al., 2012; Lieber et al., 2013) . All these advances in sequencing resulted in characterizing around 50 novel mutations, although recent reports highlight that more improvements are needed. Two independent studies carried out at hospitals in Japan and the United States show that for around 50% of the WES cases, the functional pathogenic (disease-causing) variant could not be determined (Lieber et al., 2013; Ohtake et al., 2014) . Better comparative analyses will be made possible by including more sequencing data of more cases (especially control for nonmitochondrial diseases). More reliable sequencing reactions are also needed together with efficient bioinformatics tools. In any case, assigning a highly probable variant (mutation) as a disease-causing variant remains a challenge. Therefore, functional studies on cells (depending on the availability) should be performed before making a decision about a causative DNA variant (Danhauser et al., 2011) .
Potential treatment strategies
Treatments to improve quality of life
Improving the quality of life of the patients should be the primary goal to be achieved right after the diagnosis. It has been shown that exercise therapy can help this; however, it neither stops nor prevents the occurrence of the disease. Aerobic training proved to improve OXPHOS activity and exercise capacity of patients with mitochondrial myopathy (Jeppesen et al., 2006) . Furthermore, endurance exercise improved mitochondrial myopathy symptoms in a mouse model of the disease (Wenz et al., 2009) .
Controlled and optimized diet can also help to improve quality of life. A ketogenic diet, rich in fat and low in glucose, results in high amounts of mitochondrial betaoxidation and ketone body production, which has been shown to slow the progression of mitochondrial myopathy in mice (Ahola-Erkkila et al., 2010) . Other multiple studies have shown various phenotypically beneficial effects such as reduction in epileptic seizures, improved brain energy metabolism, inhibition of ROS production, and increased neuroglia interaction and ATP concentrations (Khan et al., 2015) . Furthermore, a ketogenic diet was found to decrease the level of deleted mtDNA copies, causing a shift in heteroplasmy, in cultured human cells (Santra et al., 2004) .
Most treatment strategies for mtDNA-related diseases follow the guidelines published by the Wellcome Trust Centre for Mitochondrial Research in Newcastle, UK (http://www.newcastle-mitochondria.com/service/ patient-care-guidelines/). The discovery of mtDNA mutations and progress in our understanding of disease mechanisms have paved the way toward potential cures for mtDNA-related diseases. Experimental animal models have been very informative in defining and tailoring treatment strategies. Animal models of mtDNA-related disorders are described in a number of valuable and detailed reviews (Oliveira et al., 2010; Palladino, 2010; Dogan and Trifunovic, 2011; Dunn et al., 2012) .
Pharmacological treatments
Potential therapeutic strategies are focused on the positive effects of pharmacological and biochemical agents observed in cellular and animal models. One of the frequently observed outcomes of mtDNA-related disorders is a change (usually an increase) in the level of oxidative stress. Mitochondria are a major producer of cellular ROS and multiple mtDNA mutations have been shown to result in increased ROS. The neurodegeneration phenotype observed in LHON patients was found to be caused by increased level of ROS. Creation of cybrid lines harboring 11,778 and 3460 mutations and subsequently differentiating them into neurons resulted in increased ROS (more in 3460 mutations); however, undifferentiated cells did not show any difference (Wong et al., 2002) .
Two NARP-causing mutations at the same location (m8993T>G and m8993T>C) are reported to cause increased ROS production and SOD activity (Baracca et al., 2007) . It is worth further emphasizing that although these two mutations occur at the same location, the level of increase in ROS is different. Furthermore, increased ROS production was observed in different tissues (heart and brain) in a heteroplasmic mouse model harboring the commonly observed m3243A>G tRNA mutation (Li et al., 2008) . In view of the focus of this special issue on 'Melatonin and Mitochondria Interact in Diseases' , we detail here some of the recent advances on the potentially beneficial effects of melatonin, and specifically mtDNArelated disorders.
The hormone melatonin, secreted by the pineal gland, is a potent free-radical scavenger and regulates redoxactive enzymes (Galano et al., 2011) . Melatonin is also regarded as a possible mitochondrial protector and can restore mitochondrial function in a mouse model of Alzheimer disease involving a transgenic mutant form of APP (amyloid precursor protein) (Dragicevic et al., 2011) . More information related to the roles of melatonin in neurodegenerative process can be found in the literature (Pandi-Perumal et al., 2013) . A recent study was carried out on NARP cybrids harboring 98% heteroplasmy in the m.8993T > G mutation, which is associated with a defect in F1F0-ATP synthase. Melatonin has been reported to have the potential to rescue heart function in patients after myocardial ischemia/reperfusion (Huang et al., 2013 ), a conclusion supported by similar studies (Peng et al., 2012) . As explained earlier, the ~5-kb 'common-deletion' is widely observed in patients with mtDNA-related diseases. The increased mitochondrial ROS (mROS) production associated with the common deletion can be rescued by melatonin, preventing mROS-mediated depolarization of membrane potential (Jou et al., 2007) .
Furthermore, the lifespan-extending effect of rapamycin (Bonawitz et al., 2007; Pan et al., 2012) has been shown to have a mtDNA origin (Villa-Cuesta et al., 2014) . This further highlights the complex dual control of mitochondrial homeostasis. Potential dietary therapeutic approaches have also explored the potential of alphaketoglutarate/aspartate supplements (Sgarbi et al., 2009) . Continuing research in this area will provide additional or complementary therapeutic opportunities.
Similar approaches have been used to study the potential benefits other metabolites and vitamins, etc. Frequently cocktails of various cofactors and vitamins are being used. The choice of these agents is usually made if the molecule under question is defective, less produced, or mutated or if its transport is being impaired. Here we summarize most of the molecules used for the treatment of mitochondrial diseases. Coenzyme Q10 (CoQ10, ubiquinone) is part of the electron transport chain and it is also a ROS scavenger (Ernster and Dallner, 1995) . CoQ10 deficiency is commonly observed in various different mitochondrial diseases and CoQ10 supplementation has been overall successful (Quinzii and Hirano, 2010) . Riboflavin (watersoluble vitamin B, B 2 ) is a precursor of flavoprotein, which has key roles for complex I, complex II, the Krebs cycle, and fatty acid oxidation. Therefore, riboflavin is usually supplied in complex I and complex II diseases (Bernsen et al., 1993; Bugiani et al., 2006) . Creatine is found at high concentrations in energy-demanding tissues such as the muscle and brain. It can be classified as an energyboosting compound since it forms phosphocreatine, which is a source of high-energy phosphate. It has been used in combination with CoQ10 (Dimauro and Rustin, 2009 ). L-Arginine, which is a semiessential amino acid, has been successfully used for treatment of MELAS (Koga et al., 2002) . Carnitine, which has a key role in fatty acid metabolism, is used to increase free carnitine levels and is usually used together with CoQ10 (Marriage et al., 2004) . Dichloroacetate (DCA) is a lactic acid-lowering molecule that can be targeted to patients with increased lactate or lactic acidosis. However, a double-blinded MELAS study showed toxic effects of DCA, which resulted in decline of its use (Kaufmann et al., 2006) . Idebenone is an analogue of CoQ and has been used in LHON patients with some degree of success (Carelli et al., 2011) . Vitamins B1, C, and E and alpha-lipoic acid, dimethylglycine, and whey-based glycine are other molecules in use. For a detailed review of each of these molecules we refer to the very valuable work of others (Parikh et al., 2009; Kanabus et al., 2014) . Compounds undergoing clinical trials between 1997 and 2012 were also recently reviewed (Kerr, 2013) .
There are other pharmacological agents present on the verge of clinical trials for the treatment of mitochondrial diseases. One group of such agents with promising outcomes are focused on increasing mitochondrial biogenesis via PGC1α, PPARs, NRF1/2, YY1, and ERRs (Andreux et al., 2013) . Bezafibrate, which is a synthetic ligand of PPARα, has been proposed to be a new pharmacological agent supported by several positive results obtained in mouse models (Kanabus et al., 2014) . A clinical trial of bezafibrate in mitochondrial disorders is missing, although promising observations were made in a clinical trial of a fatty acid oxidation disorder called carnitine palmitoyl transferase 2 (CPT2) deficiency (Bonnefont et al., 2010) . Another candidate targeting mitochondrial biogenesis is resveratrol, which is an activator of sirtuin SIRT1. Until now, resveratrol has only been included in a clinical trial of healthy elderly individuals (rather than mitochondrial disease patients), and increased mitochondrial function was observed (Libri et al., 2012) . Finally, AICAR, which is an AMPK activator, was tested in human complex I-deficient fibroblasts and promising results were obtained, such as increased ATP levels and decreased ROS (Golubitzky et al., 2011) . In summary, very detailed clinical trials are needed in order to determine the benefits of using mitochondrial biogenesis activators as new therapeutic agents.
In addition to ROS, other toxic substances such as hydrogen sulfide (H 2 S) are also the target of some potential treatments. It has been shown that NAC and metronidazole treatment is useful for ethylmalonic encephalopathy (Viscomi et al., 2010) . Furthermore, targeting mitochondrial dynamics, autophagy, and mitochondrial membrane lipids are other possibilities that need to be investigated at the preclinical level (Andreux et al., 2013) .
Gene therapy
Current treatment strategies are aimed at ameliorating symptoms and reducing the risk of complications. Cure and prevention of mtDNA-related diseases, however, requires more effective treatments. The primary goal for an effective gene therapy of mtDNA-related diseases is to alter the level of heteroplasmy, either by targeted degradation of mutant mtDNA or by blocking replication (Taylor et al., 1997) .
The earliest gene therapy trials, started in the late 1990s, tested the potential of mitochondria-targeted peptide nucleic acid (PNA) oligomers, which are DNAlike molecules with an aminoglycine backbone instead of phosphate ribose groups. In vitro assays showed that this technique could prevent replication of mutant mtDNA copies; however, cell line studies were less successful .
The next approach tried was to target mitochondrial genes with endonucleases. The m.8993T > G mutation is known to generate a specific SmaI endonuclease cleavage site. Therefore, delivery of SmaI to mitochondria containing the mutant mtDNA has the potential to deplete mutant mtDNA copies and result in biochemical rescue (Tanaka et al., 2002) . Further advances in this field have been made possible by the use of chimeric zinc finger methylases (Minczuk et al., 2006) . Use of specific zinc finger peptides (ZFPs) to target the m.8993T > G mutation resulted in reduction of heteroplasmy over a 30-day period (Minczuk et al., 2008) . More recently, the development of transcription activator-like effectors (TALEs) and TALE nucleases (TALENs) has produced very promising results for mtDNA gene therapy (Boch et al., 2009; Hockemeyer et al., 2011) . The use of TALENs resulted in reductions in heteroplasmy from 70% to 30% without affecting mtDNA copy number (Bacman et al., 2012) . Supporting results have also been reported in a cybrid cell model of the common deletion (Gammage et al., 2014) . Detailed analysis of these improvements are needed, and these techniques and their potential uses were critically evaluated in recent reviews (Kaufmann et al., 2013; Moraes et al., 2014) . Furthermore, it has been reported recently that the transmission of mtDNA mutations can be prevented in the germline by the use of TALENs to eliminate mutated mtDNA copies (Reddy et al., 2015) . The same group also adapted the 'MitoTALENs' technology, so they can be used by viral delivery vectors (Hashimoto et al., 2015) . The common expectation in the field is to start testing this technology on patients who are waiting to be treated.
Genetic counseling
One of the most ideal strategies is to prevent mtDNArelated disease before it occurs. Therefore, genetic counseling and prenatal diagnosis have started to be applied. Informing parents about the real risk of having a child with a mitochondrial disease should be done by professionals.
Mechanism of transmission and segregation of mtDNA species (mutated and nonmutated) in the germline is not fully understood; therefore, prenatal genetic diagnosis resulted in limited success ). Although it is not possible to estimate heteroplasmy levels in individual tissues, and therefore not possible to predict clinical outcomes, prenatal genetic diagnosis has reportedly been applied successfully in several cases (Bouchet et al., 2006) . Due to these uncertainties, parents are aiming to have offspring without any mutated mtDNA copies by the help of preimplantation genetic diagnosis (PGD) (Hellebrekers et al., 2012) .
Concluding remarks
Mitochondria are central to many processes in the cell, and disturbances to ATP metabolism trigger a wide range of symptoms. Increasing evidence has implicated mtDNA defects in numerous diseases such as LHON, MELAS, PEO, NARP, MILS, KSS, and Pearson syndrome and also in broader diseases such as neurodegeneration and cancer. A healthy mtDNA population is vital for the maintenance of efficient ATP production. However, further detailed research into the mechanisms of mtDNA-related diseases is required to develop effective diagnostic and treatment options. Recent advances in NGS discussed here will be particularly useful for effective diagnosis of patients. More detailed clinical trials incorporating mtDNA-related targets promise optimized pharmacological treatments in the coming years. Recent improvements in gene therapy are very promising, especially the use of TALENs, which has been successfully reported for the treatment of LHON and NARP. The first clinical trials of gene therapy are expected to start in the next few years. Global, multidisciplinary, and collaborative work on mtDNA-related diseases will be fundamental for the discovery of effective diagnostic and therapeutic strategies.
